Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study
Pyrotinib plus trastuzumab demonstrates clinically meaningful efficacy and a manageable safety profile in heavily pretreated HER2-positive metastatic colorectal cancer. These findings support advancing this regimen as a potential alternative in refractory HER2-positive mCRC, particularly in the RAS/BRAF wild-type subgroup.
Authors
- Guifu Wu (ORCID: https://orcid.org/0000-0002-2823-6643)
- Aiping Zhou
- Wenwei Yang (ORCID: https://orcid.org/0000-0002-7292-5980)
- Yongkun Sun (ORCID: https://orcid.org/0000-0003-3302-6023)
- Lin Yang (ORCID: https://orcid.org/0000-0003-4668-0083)
- Wen Zhang (ORCID: https://orcid.org/0000-0003-3150-2751)
- Jing Zhang (ORCID: https://orcid.org/0000-0003-2230-5465)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-11-01
- DOI
- https://doi.org/10.2147/dddt.s558378
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- Cancer Foundation of China